Loading...

PE anti-mouse CD206 (MMR) Antibody

Pricing & Availability
Clone
C068C2 (See other available formats)
Regulatory Status
RUO
Other Names
MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
C068C2_PE_1_082911
Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) APC, and then intracellularly stained with CD206 (clone C068C2) PE (top) or rat IgG2a, κ PE isotype control (bottom).
  • C068C2_PE_1_082911
    Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) APC, and then intracellularly stained with CD206 (clone C068C2) PE (top) or rat IgG2a, κ PE isotype control (bottom).
  • C068C2_PE_2_082911
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
141705 25 µg 104€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
141706 100 µg 240€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant mouse CD206 (MMR)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume.  It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.

Application References

(PubMed link indicates BioLegend citation)
  1. Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed
  2. Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed
  3. Yang X, et al. 2015. PNAS. 112:2900. PubMed
  4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Cui J, et al. 2021. J Cell Mol Med. 25:5586. PubMed
  2. Yu L, et al. 2021. Cell Biol Int. 45:2452. PubMed
  3. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  4. Silveira DB, et al. 2022. Cell Biochem Funct. 40:163. PubMed
  5. Liang X, et al. 2022. Cancer Commun (Lond). 42:205. PubMed
  6. Lee R, et al. 2022. Cancer Discov. 12:1702. PubMed
  7. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  8. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  9. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  10. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  11. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  12. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  13. Li J, et al. 2023. Front Immunol. 13:945234. PubMed
  14. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  15. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  16. Li Y, et al. 2023. Cell Death Dis. 14:28. PubMed
  17. Zhang L, et al. 2023. J Inflamm Res. 16:109. PubMed
  18. Fan R, et al. 2023. J Immunother Cancer. 11: . PubMed
  19. Chun J, et al. 2023. Cancers (Basel). 15: . PubMed
  20. Li S, et al. 2023. Exp Mol Med. 55:457. PubMed
  21. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  22. Lundahl MLE, et al. 2022. Elife. 11:. PubMed
  23. Adzika GK, et al. 2023. Front Immunol. 14:1124649. PubMed
  24. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  25. Garabuczi É, et al. 2023. Front Immunol. 14:1139204. PubMed
  26. Chung JY, et al. 2023. Nat Commun. 14:1794. PubMed
  27. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  28. Pan C, et al. 2023. Front Bioeng Biotechnol. 11:1129187. PubMed
  29. Levra Levron C, et al. 2023. Nat Cell Biol. 25:740. PubMed
  30. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  31. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  32. Salemme V, et al. 2023. Nat Commun. 14:2350. PubMed
  33. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  34. Xiong Y, et al. 2020. J Nanobiotechnology. 18:66. PubMed
  35. Zhang B, et al. 2022. Front Med (Lausanne). 8:796743. PubMed
  36. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  37. Zhang Z, et al. 2022. Front Pharmacol. 13:906625. PubMed
  38. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  39. Feng Y, et al. 2018. J Am Soc Nephrol. 29:182. PubMed
  40. Seo JB, et al. 2019. Nat Metab. 1:86. PubMed
  41. Ying W, et al. 2019. Cell Metab. 29:457. PubMed
  42. Sun H, et al. 2019. Mol Hum Reprod. 25:05:00. PubMed
  43. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
  44. Hu S, et al. 2018. Front Immunol. 9:01. PubMed
  45. Ying W et al. 2017. Cell. 171(2):372-384 . PubMed
  46. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  47. Zheng W, et al. 2021. Wellcome Open Research. 6:52. PubMed
  48. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  49. Dong L, et al. 2021. Cancer Cell. . PubMed
  50. Sadek J, et al. 2021. EMBO Mol Med. 13:e13591. PubMed
  51. Nomura M, et al. 2016. Nat Immunol. 17:216-217. PubMed
  52. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  53. Li Q, et al. 2021. Front Immunol. 12:707784. PubMed
  54. Clarke F,et al. 2017. PLoS One. 10.1371/journal.pone.0186625. PubMed
  55. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  56. Pajarinen J, et al. 2021. J Biomed Mater Res A. 109:1512. PubMed
  57. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  58. De Vlaeminck Y, et al. 2020. Cancers (Basel). 12:. PubMed
  59. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  60. Krukowski K, et al. 2021. Sci Adv. 7:eabg6702. PubMed
  61. Shao H, et al. 2012. J Biol Chem. 287:35860. PubMed
  62. Jia X, et al. 2021. Front Cell Dev Biol. 9:685522. PubMed
  63. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  64. Tang TT, et al. 2020. Sci Adv. 6:eaaz0748. PubMed
  65. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  66. Zhang J, et al. 2021. J Leukoc Biol. 110:485. PubMed
  67. Tanner L, et al. 2022. Front Pharmacol. 13:899469. PubMed
  68. Hou H, et al. 2021. Front Cell Dev Biol. 9:737003. PubMed
  69. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  70. El–Achkar GA, et al. 2019. PLoS One. 14:e0216405. PubMed
  71. McKee AM, et al. 2021. iScience. 24:103012. PubMed
  72. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  73. Giri J, et al. 2020. Cell Rep. 30:1923. PubMed
  74. Dan H, et al. 2020. Mol Oncol. 14:795. PubMed
  75. Kim JS, et al. 2020. Int J Oncol. 56:1405. PubMed
  76. Zhang Y, et al. 2022. Nat Commun. 13:4553. PubMed
  77. Martins L, et al. 2020. Stem Cell Res Ther. 0.786805556. PubMed
  78. Farini A, et al. 2020. Front Physiol. 0.738194444. PubMed
  79. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  80. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  81. Jiao Y, et al. 2021. Crit Care. 25:356. PubMed
  82. An W et al. 2019. British journal of pharmacology. 176(5):699-710 . PubMed
  83. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  84. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  85. Lu X, et al. 2020. Sci Transl Med. 12:. PubMed
  86. Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed
  87. Cai C, et al. 2021. Sci Rep. 11:13386. PubMed
  88. Toubal A, et al. 2020. Nat Commun. 3755:11. PubMed
  89. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  90. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  91. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  92. Golden TN, et al. 2022. Front Pharmacol. 12:761496. PubMed
  93. Lee DH, et al. 2019. PLoS One. 14:e0215727. PubMed
  94. Yu Y, et al. 2018. Mol Med Rep. 17:8212. PubMed
  95. Miura I, et al. 2021. Physiol Rep. 9:e14859. PubMed
  96. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  97. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  98. Ruiz de Azua I, et al. 2017. J Clin Invest. 127:4148. PubMed
  99. Shu Y, et al. 2020. Immunology. 160:345. PubMed
  100. Ying W, et al. 2016. Sci Rep. 6:20176. PubMed
  101. Sztwiertnia I, et al. 2020. PLoS One. 15:e0233789. PubMed
  102. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  103. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  104. Chu SY, et al. 2019. Nat Commun. 10:1524. PubMed
  105. Lu X, et al. 2012. Arterioscler Thromb Vasc Biol. 32:2358. PubMed
  106. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  107. Yang C, et al. 2022. Nat Commun. 13:4866. PubMed
  108. Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed
  109. Lowe PP, et al. 2020. J Neuroinflammation. 0.913888889. PubMed
  110. Zhou K, et al. 2016. J Cereb Blood Flow Metab. 10.1177/0271678X16648712. PubMed
  111. Deng W, et al. 2015. Clin Immunol. . PubMed
  112. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  113. Anderson-Baucum E, et al. 2021. Cell Metab. 33:1883. PubMed
  114. Stevenson ER, et al. 2022. J Pharmacol Exp Ther. 382:356. PubMed
  115. Wang X, et al. 2022. J Biol Chem. 298:101561. PubMed
  116. Stridh L, et al. 2013. J Neurosci. 33:12401. PubMed
  117. Zhu Q, et al. 2022. Atherosclerosis. 357:41. PubMed
  118. Asterholm I, et al. 2012. J Lipid Res. 53: 1254. PubMed
  119. Budai Z, et al. 2021. Cells. 10:. PubMed
  120. Long L, et al. 2018. Bio Protoc. 8:e2815. PubMed
  121. Li C, et al. 2019. JCI Insight. 5. PubMed
  122. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  123. Di Lorenzo A, et al. 2022. Oncoimmunology. 11:2086752. PubMed
  124. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  125. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  126. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  127. Krukowski K, et al. 2018. Sci Rep. 8:7857. PubMed
  128. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  129. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  130. Liu C, et al. 2022. Cell Death Discov. 8:269. PubMed
  131. Ukah T, et al. 2017. J Immunol. 10.4049/jimmunol.1700410. PubMed
  132. Roediger B et al. 2018. Cell. 175(2):530-543 . PubMed
  133. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  134. Budhu S, et al. 2021. Cell Reports. 34(2):108620. PubMed
  135. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  136. Browne A, et al. 2015. Cancer Res . 75: 2811 - 2821. PubMed
  137. Moreno M et al. 2014. The Journal of Neuroscience. 34(24):8175-85 . PubMed
  138. Zhang J, et al. 2020. J Cell Mol Med. 24:4547. PubMed
  139. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  140. Al-Zaeed N, et al. 2021. Cell Death Dis. 12:611. PubMed
  141. Golabek A, et al. 2021. Exp Ther Med. 21:482. PubMed
  142. Yuan Y, et al. 2019. Clin Sci (Lond). 133:1759. PubMed
  143. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  144. Yeini E, et al. 2021. Nat Commun. 12:1912. PubMed
  145. Xu GY, et al. 2022. Small. 18:e2107838. PubMed
  146. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  147. Li B et al. 2019. Cell reports. 26(10):2720-2737 . PubMed
  148. Morioka S, et al. 2018. Nature. 563:714. PubMed
  149. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
  150. Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed
  151. Cai T, et al. 2022. Front Immunol. 13:1009932. PubMed
  152. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  153. Guo S, et al. 2021. Chronic Dis Transl Med. 7:254. PubMed
  154. Chuan Li et al. 2017. Endocrinology. 158(9):2837-2847 . PubMed
  155. Wen HJ, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:p173. PubMed
  156. Yuan M, et al. 2017. Hum Reprod. 32:94. PubMed
  157. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  158. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_10896421 (BioLegend Cat. No. 141705)
AB_10895754 (BioLegend Cat. No. 141706)

Antigen Details

Structure
Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution

Macrophages, dendritic cells, Langerhans cells, liver endothelial cells

Function
Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor
Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type
Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References

1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501.
2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469.
3. Burgdorf S, et al. 2006. J. Immunol. 176:6770.
4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.

Gene ID
17533 View all products for this Gene ID
UniProt
View information about CD206 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Why is mouse CD206 stained intracellularly and not via surface staining?

Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.

Go To Top Version: 3    Revision Date: 04/04/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account